Citation:Katakami N, Tada H, Mitsudomi T, Kudoh S, Senba H, Matsui K, et al 2012

Citation

Katakami N, Tada H, Mitsudomi T, Kudoh S, Senba H, Matsui K, et al. A phase 3 study of induction treatment with concurrent chemoradiotherapy versus chemotherapy before surgery in patients with pathologically confirmed N2 stage IIIA nonsmall cell lung cancer (WJTOG9903). Cancer 2012 Jun 6 Available from: http://www.ncbi.nlm.nih.gov/pubmed/22674529.

Critical appraisals

• Assign a critical appraisal

Critical appraisal link	Clinical question	Assigned to	Status
Katakami N, Tada H, Mitsudomi T, Kudoh S, Senba H, Matsui K, et al 2012	What is the clinical benefit of neoadjuvant chemotherapy for patients with stage III operable NSCLC?	Professor Michael Brown MBBS PhD FRACP FRCPA	completed
Katakami N, Tada H, Mitsudomi T, Kudoh S, Senba H, Matsui K, et al 2012 2	What is the clinical benefit of the addition of surgery to definitive chemoradiotherapy in stage IIIA (N2) NSCLC? What is the clinical benefit of the addition of neoadjuvant radiotherapy to neoadjuvant chemotherapy in stage IIIA (N2) NSCLC?	Dr Stephen Barnett	completed

Compare quality appraisals for each clinical question

• [[Clinical question:What is the clinical benefit of neoadjuvant chemotherapy for patients with stage III operable NSCLC?|]] (compare critical appraisals)
• [[Clinical question:What is the clinical benefit of the addition of surgery to definitive chemoradiotherapy in stage IIIA (N2) NSCLC?, Clinical question:What is the clinical benefit of the addition of neoadjuvant radiotherapy to neoadjuvant chemotherapy in stage IIIA (N2) NSCLC?|]] (compare critical appraisals)

Cited by

1. Emma.dickins/Sandbox
2. What is the clinical benefit of neoadjuvant chemotherapy for patients with stage III operable NSCLC?